Drug Trial Radar · NCT06064877
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
410
Planned (sponsor's estimate)
Start
Jan 11, 2024
Primary completion
Aug 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- AVEO Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.
Conditions
- Metastatic Head-and-neck Squamous-cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
FiclatuzumabBiological
Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).
CetuximabBiological
Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
PlaceboOther
Placebo for this study will be normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare the efficacy by overall survival of ficlatuzumab plus cetuximab vs placebo plus cetuximab in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)Time frame: From Randomization until death from any cause (Approximately 44 months)
Locations
112 sites in 18 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona · Recruiting
The University of Arizona Cancer Center
Tucson, Arizona · Recruiting
University of California Los Angeles
Los Angeles, California · Recruiting
Yale School of Medicine - Smilow Cancer Hospital
New Haven, Connecticut · Recruiting
The George Washington University
Washington D.C., District of Columbia · Recruiting
AdventHealth Medical Group Oncology & Hematology at Orlando
Orlando, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Emory University
Atlanta, Georgia · Recruiting
University of Illinois Cancer Center
Chicago, Illinois · Recruiting
University of Kansas Cancer Center
Westwood, Kansas · Recruiting
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana · Recruiting
MaineHealth Institute for Research
South Portland, Maine · Recruiting
University of Maryland
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Siteman Cancer Center - Washington University
St Louis, Missouri · Recruiting
Northwell Health Cancer Institute
Lake Success, New York · Recruiting
Manhattan Eye, Ear & Throat Hospital
New York, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Withdrawn
University of Cincinnati - UC Health Barrett Cancer Center
Cincinnati, Ohio · Withdrawn
Ohio State University, James Cancer Hospital and Solove Research Institute
Columbus, Ohio · Recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Recruiting
University of Pittsburgh Medical Center - Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Medical University of South Carolina (MUSC)
Charleston, South Carolina · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Oncology Consultants
Houston, Texas · Recruiting
VCU Massey Cancer Center
Richmond, Virginia · Recruiting
Medical College of Wisconsin - Froedtert Hospital Cancer Center
Milwaukee, Wisconsin · Terminated
St George Hospital
Kogarah, New South Wales, Australia · Recruiting
St. Vincent's Hospital
Sydney, New South Wales, Australia · Recruiting
Princess Alexandra Hospital
Brisbane, Queensland, Australia · Recruiting
St. John of God Murdoch Hospital
Murdoch, Western Australia, Australia · Recruiting
CHU Liège
Liège, Belgium · Recruiting
CHU Universite Catholique de Louvain
Namur, Belgium · Recruiting
Vitaz-Sint-Niklaas Moerland
Sint-Niklaas, Belgium · Recruiting
University Hospital
Panagyurishte, Bulgaria · Withdrawn
Tom Baker Cancer Centre (Alberta Health Services)
Calgary, Alberta, Canada · Recruiting
Cross Cancer Institute
Edmonton, Alberta, Canada · Recruiting
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada · Withdrawn
Princess Margaret Cancer Center - University Health Network
Toronto, Ontario, Canada · Recruiting
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.